The potential role of pharmacotherapy in somatoform disorders

Reviews in Contemporary Pharmacotherapy

Volumn 7, Issue 6, 1996, Pages 287-298

  Douki, S ^a   Bouzid, R ^a   Taktak, J ^a   Tabane, K ^a   Ben Abid, J ^a  

^a RAZI HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000797148     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Allagille M. Les troubles psychosomatiques. Comment les reconnaitre et les prendre en charge? Rev Practic Méd Gén 1993; 7: 47-56.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, edn 3. Washington: American Psychiatric Association, 1980.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, edn 4, Washington: American Psychiatric Association, 1994.
4. Bass C, Benjamin S. The management of chronic somatisation. Br J Psychiatry 1993; 162: 472-480.
5. Bass C, Potts S. Somatoform disorders. In: Grossman KG, ed. Advances in clinical psychiatry, Vol 8. Edinburgh: Churchill-Livingstone, 1993: 143-163.
6. Baugmann OL. Rapid diagnosis and treatment of anxiety and depression in primary care: the somatizing patient. Fam Pract 1994; 39: 373-378.
7. Besançon G, Servillat Th, Albert E. Les médicaments du stress. L'Encéphale 1993; 19: 203-207.
8. Budde G. Efficacy and tolerability of flupentixol decanoate in the treatment of depression and psychosomatic disorders: a multicenter trial in general practice. Prog Neuropsychopharmacol Biol Psychiatry 1992; 16: 677-689.
9. Caponeri MA, Cichetti V. Impiego del Middlesex Hospital Questionnaire (MHQ) in ambito psicosomatico. Clin Ter 1978; 87: 51-67.
10. Casey PR. A guide to psychiatry in primary care. Petersfield: Wrightson Biomedical Publishing, 1990.
11. Costall B, Naylor RJ. The substituted benzamides: selective dopamine receptor blockade. In: Ackenheil M, Matuseek N, eds. Special aspects of psychopharmacology. Possible clinical significance of recent biochemical and pharmacological findings with ortho-methoxybenzamines. Paris: Expansion Scientifique Française, 1983; 41-17.
12. Shorter E, Abbey SE, Gillies LA, Singh M, Lipowski ZJ. Inpatient treatment of persistent somatisation. Psychosomatics, 1992; 33: 295-301.
13. Toru M, Moriya H, Yamamoti K, Shimazono Y. A double-blind comparison of sulpiride with chlordiazepoxide in neurosis. Folia Psychiatr Neurol Japon 1976; 30: 153-164.
14. Turnheim K. Plazebo als unspezifischer Behandlungsfaktor. Wien Klin Woschenschr 1987; 99: 705-710.
15. Volz HP, Stieglitz RD, Menges KE, Möller HJ. Somatoform disorders - diagnostic concept, controlled clinical trials and methodological issues. Pharmacopsychiatry 1994; 27: 231-237.
16. Von Knorring L. Common pathogenic mechanisms in chronic pain syndromes and in depressive disorders. In: Racagni G, Brunelle N, Fukudu T, eds. Biological psychiatry. Vol. 1. Amsterdam: Excerpta Medica, 1991: 237-239.
17. Zitman FG, Linssen ACG, Edelbroek PM, Van Kampen GMJ. Does addition of low-dose flupenthixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder? Pain 1991; 47: 25-30.